Pharmaceutical Technology on MSN15h
EMA to review GSK’s Nucala for COPD treatment expansionThe European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...
Zacks Investment Research on MSN1d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPDGSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback